Children exposed in utero to certain synthetic chemicals known as PFAS had higher blood pressure in adolescence, according to findings published in the Journal of the American Heart Association and ...

The FDA has extended its review of Incyte’s supplemental New Drug Application (sNDA) for ruxolitinib cream 0.75% (Opzelura) for the treatment of mild to moderate atopic dermatitis (AD) in children ...

On June 18, Biogen announced the dosing of participants in the BRAVE study (NCT06953583), a global phase 3 clinical trial evaluating omaveloxolone (Skyclarys) in children aged 2 to younger than 16 ...

The nearly 4000 cases in 2023 were the highest number reported in over 30 years, the Task Force stated ...

As RSV prevention tools expanded, clinicians faced new decisions around allocation, coordination, and outreach. In the final installment of this 3-part HCP Live Network RX Review roundtable, moderator ...

Vimkunya for aged 12 and older launched in March Vimkunya was launched on March 18, 2025, for individuals aged 12 years and older, following its approval on February 14, 2025. The approval made it the ...

The label expansion allows for immediate treatment at diagnosis in patients aged ≥3 years without cirrhosis or with compensated cirrhosis. In a phase 3 trial, 96.2% of patients with acute HCV achieved ...

A study recently published in JAMA Pediatrics found that US states with permissive firearm laws saw significantly more pediatric firearm deaths following the 2010 Supreme Court ruling in McDonald v ...